Inuk Zandvakili, MD, PhD
Adjunct Assistant Professor of Medicine (Gastroenterology)
Department: Medicine
Contact information
University of Cincinnati College of Medicine
3230 Eden Avenue
Cincinnati, OH 45267
3230 Eden Avenue
Cincinnati, OH 45267
Education:
BS (Biochemistry)
University of Western Ontario, 2006.
PhD (Molecular and Developmental Biology)
University of Cincinnati, 2015.
MD (Medicine)
University of Cincinnati, 2016.
BS (Biochemistry)
University of Western Ontario, 2006.
PhD (Molecular and Developmental Biology)
University of Cincinnati, 2015.
MD (Medicine)
University of Cincinnati, 2016.
Post-Graduate Training
Resident - Internal Medicine (Categorical), Mayo Clinic, 2016-2019.
Fellow - Gastroenterology, University of Pennsylvania, 2019-2022.
Permanent linkResident - Internal Medicine (Categorical), Mayo Clinic, 2016-2019.
Fellow - Gastroenterology, University of Pennsylvania, 2019-2022.
Description of Clinical Expertise
I treat general gastrointestinal diseases and conditions, as well as specialize in medical weight loss therapy.Description of Research Expertise
I am interested in the role of gut hormones in the development of obesity and obesity related diseases such as non-alcohol fatty liver disease (NAFLD). Gut hormones such as GLP1, GIP and PYY are involved in appetite and metabolism and are current or potential therapeutic targets for the treatment of obesity (as are the receptors for these hormones). I am interested in genomic and translational, human-subject, research into gut hormones and obesity. My expertise and interests include cell based research, murine genetics and murine research, deep phenotyping of human subjects, genomics and bioinformatic approaches to large datasets.Selected Publications
Scorletti E, Creasy KT, Vujkovic M, Vell M, Zandvakili I, Rader DJ, Schneider KM, Schneider CV: Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 117(6): 927-30, Jun 2022.Sehgal K, Zandvakili I, Tariq R, Pardi DS, Khanna S: Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. Expert Rev Anti Infect Ther 20(4): 577-83, Apr 2022.
Schneider CV, Schneider KM, Conlon DM, Park J, Vujkovic M, Zandvakili I, Ko YA, Trautwein C, Center R, Carr RM, Strnad P, Thaiss CA, Rader DJ: A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes. Med (N Y) 2(7): 851-863, Jul 2021.
Schneider CV, Zandvakili I, Thaiss CA, Schneider KM: Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort. JHEP Rep 3(3): 100263, Mar 2021.
Calderon G, McRae A, Rievaj J, Davis J, Zandvakili I, Linker-Nord S, Burton D, Roberts G, Reimann F, Gedulin B, Vella A, LaRusso NF, Camilleri M, Gribble FM, Acosta A: Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine 55(102759): 10.1016, May 2020.
Zandvakili I, Lloyd JW, Giridhar KV: Hepatitis, Pancreatitis and Rash in a Patient With Chronic Lymphocytic Leukemia. Gastroenterology 157(4): e8-9, Oct 2019.
Zandvakili I, Lazaridis KN.: Cell-free DNA testing: future applications in gastroenterology and hepatology. Therap Adv Gastroenterol 12: 1756284819841896, Apr 2019.
Gerardo Calderon, Alison N Bonis, Judith Davis, Inuk Zandvakili, Sara Linker Nord, Duane Burton, Adrian Vella, Nicholas F LaRusso, Bronislava Gedulin, Michael Camilleri, Andres Acosta: Modulation of Bile Acids Pathway in Obesity and Type 2 Diabetes. Gastroenterology 156: S-93, 2019 Notes: Poster presentation.
Alison N Bonis, Gerardo Calderon, William Rossini, Inuk Zandvakili, Geoffrey Roberts, Fiona Gribble, Andres Acosta: A Protocol for Live-FACS from Cryopreserved Human Colonic Mucosal Biopsies Compatible with Single Cell Transcriptomics. Gastroenterology 156, 2019 Notes: Poster presentation.
Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A: Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. Am J Hematol 93(5): e123-5, May 2018.
Contact us
Institute for Diabetes, Obesity and Metabolism
Smilow Center for Translational Research
3400 Civic Center Boulevard, 12th Floor
Philadelphia, PA 19104
Phone: 215-898-0198 | Fax 215-898-5408
Directions
© Trustees of the University of Pennsylvania